Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Rayno Life Science Stocks Rally: ALXN, BIIB, GILD, REGN, RHHBY( New)

|Includes:Cardiovascular Systems, Inc. (CSII), IBB, RHHBY

Update 12:40p NASDAQ Up 2%

Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2.

Thermo Fisher (TMO$114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to $3.47B.

All Rayno stocks are green today except Nanosphere (NASDAQ:NSPH) and Qiagen (NASDAQ:QGEN).

Biotech Rally Resumes With Large Caps-IBB up 3.2%

Alexion (ALXN$155) soars 15% on Q4 and Full Year Results

Product sales increased 37% to $1.55B, GAAP Net Income was $252.9M or $1.27/share Guides above consensus. The stock was added to the Rayno Portfolio on 2/2/09 at a price of $35.

Biogen (BIIB $313) back up 2.4%on 2013 Earnings, Conservative guidance.

Gilead (NASDAQ:GILD) and Regeneron (NASDAQ:REGN) stocks also up about 2%.

Vertex (VRTX $83.50) up 5.94% on disappointing guidance? 2013 Revenues of $1.21 B. 2013 GAAP loss of $445M. Incivek HCV sales were down.We added VRTX in November at a price of $63.However Q$ was profitable because of a royalty deal in Europe on Incivek. Guidance for revenue for 2014 is $570M-600M.

Adding Roche Holding (OTCQX:RHHBY$67) to Rayno Portfolio based on J.P.Morgan Healthcare Presentation. Largest Company pure play in biopharma and diagnostics.

Disclosure: I am long CSII, RHHBY.

Additional disclosure: I am long FBIOX Fidelity Select Biotechnology Fund